OncoMatch/Clinical Trials/NCT04485286
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Is NCT04485286 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies [68Ga]CBP8 for lung cancer.
Treatment: [68Ga]CBP8 — The goal of this study is to investigate the efficacy of \[68Ga\]CBP8 to detect collagen deposition in radiation induced tissue injury.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Pancreatic Cancer
Disease stage
Required: Stage I, II, III, IIIA
Demographics
Lab requirements
Kidney function
eGFR of less than 30 mL/min/1.73 m2 within the past 90 days [excluded]
eGFR of less than 30 mL/min/1.73 m2 within the past 90 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04485286 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage I or II or III or IIIA is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify